 Connection
Timothy McKinsey to Heart Failure
This is a "connection" page, showing publications Timothy McKinsey has written about Heart Failure.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.937 |
|
|
|
-
Salyer LG, Wang Y, Ma X, Foryst-Ludwig A, Kintscher U, Chennappan S, Kontaridis MI, McKinsey TA. Modulating the Secretome of Fat to Treat Heart Failure. Circ Res. 2025 May 23; 136(11):1363-1381.
Score: 0.380
-
Delaunay M, Jebessa ZH, McKinsey TA. Cyclophilin(g) a Knowledge Gap in Heart Failure Pathogenesis. Circ Res. 2024 Sep 13; 135(7):774-776.
Score: 0.362
-
McKinsey TA, Foo R, Anene-Nzelu CG, Travers JG, Vagnozzi RJ, Weber N, Thum T. Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development. Cardiovasc Res. 2023 02 03; 118(18):3482-3498.
Score: 0.324
-
Rubino M, Travers JG, Headrick AL, Enyart BT, Lemieux ME, Cavasin MA, Schwisow JA, Hardy EJ, Kaltenbacher KJ, Felisbino MB, Jonas E, Ambardekar AV, Bristow MR, Koch KA, McKinsey TA. Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart. Circ Res. 2023 01 06; 132(1):10-29.
Score: 0.321
-
Tharp CA, McKinsey TA. Tissue is the issue: Endomyocardial biopsies to elucidate molecular mechanisms and tailor therapy for HFpEF. J Mol Cell Cardiol. 2022 08; 169:111-112.
Score: 0.309
-
Travers JG, Tharp CA, Rubino M, McKinsey TA. Therapeutic targets for cardiac fibrosis: from old school to next-gen. J Clin Invest. 2022 03 01; 132(5).
Score: 0.304
-
Ambardekar AV, Stratton MS, Dobrinskikh E, Hunter KS, Tatman PD, Lemieux ME, Cleveland JC, Tuder RM, Weiser-Evans MCM, Moulton KS, McKinsey TA. Matrix-Degrading Enzyme Expression and Aortic Fibrosis During Continuous-Flow Left Ventricular Mechanical Support. J Am Coll Cardiol. 2021 11 02; 78(18):1782-1795.
Score: 0.297
-
Stratton MS, Bagchi RA, Felisbino MB, Hirsch RA, Smith HE, Riching AS, Enyart BY, Koch KA, Cavasin MA, Alexanian M, Song K, Qi J, Lemieux ME, Srivastava D, Lam MPY, Haldar SM, Lin CY, McKinsey TA. Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. Circ Res. 2019 09 13; 125(7):662-677.
Score: 0.255
-
McKinsey TA, Vondriska TM, Wang Y. Epigenomic regulation of heart failure: integrating histone marks, long noncoding RNAs, and chromatin architecture. F1000Res. 2018; 7.
Score: 0.241
-
Stratton MS, McKinsey TA. Epigenetic regulation of cardiac fibrosis. J Mol Cell Cardiol. 2016 Mar; 92:206-13.
Score: 0.200
-
Ferguson BS, McKinsey TA. Non-sirtuin histone deacetylases in the control of cardiac aging. J Mol Cell Cardiol. 2015 Jun; 83:14-20.
Score: 0.188
-
Demos-Davies KM, Ferguson BS, Cavasin MA, Mahaffey JH, Williams SM, Spiltoir JI, Schuetze KB, Horn TR, Chen B, Ferrara C, Scellini B, Piroddi N, Tesi C, Poggesi C, Jeong MY, McKinsey TA. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am J Physiol Heart Circ Physiol. 2014 Jul 15; 307(2):H252-8.
Score: 0.177
-
Haldar SM, McKinsey TA. BET-ting on chromatin-based therapeutics for heart failure. J Mol Cell Cardiol. 2014 Sep; 74:98-102.
Score: 0.177
-
McKinsey TA. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol. 2012; 52:303-19.
Score: 0.148
-
McKinsey TA. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med. 2011 May-Jun; 17(5-6):434-41.
Score: 0.141
-
McKinsey TA. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J Mol Cell Cardiol. 2011 Oct; 51(4):491-6.
Score: 0.139
-
Bush EW, McKinsey TA. Targeting histone deacetylases for heart failure. Expert Opin Ther Targets. 2009 Jul; 13(7):767-84.
Score: 0.126
-
Alexanian M, Padmanabhan A, Nishino T, Travers JG, Ye L, Pelonero A, Lee CY, Sadagopan N, Huang Y, Auclair K, Zhu A, An Y, Ekstrand CA, Martinez C, Teran BG, Flanigan WR, Kim CK, Lumbao-Conradson K, Gardner Z, Li L, Costa MW, Jain R, Charo I, Combes AJ, Haldar SM, Pollard KS, Vagnozzi RJ, McKinsey TA, Przytycki PF, Srivastava D. Chromatin remodelling drives immune cell-fibroblast communication in heart failure. Nature. 2024 Nov; 635(8038):434-443.
Score: 0.091
-
Li Y, Kubo H, Yu D, Yang Y, Johnson JP, Eaton DM, Berretta RM, Foster M, McKinsey TA, Yu J, Elrod JW, Chen X, Houser SR. Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype. Am J Physiol Heart Circ Physiol. 2023 04 01; 324(4):H443-H460.
Score: 0.081
-
Felker GM, Buttrick P, Rosenzweig A, Abel ED, Allen LA, Bristow M, Das S, DeVore AD, Drakos SG, Fang JC, Freedman JE, Hernandez AF, Li DY, McKinsey TA, Newton-Cheh C, Rogers JG, Shah RV, Shah SH, Stehlik J, Selzman CH. Heart Failure Strategically Focused Research Network: Summary of Results and Future Directions. J Am Heart Assoc. 2022 09 20; 11(18):e025517.
Score: 0.079
-
Eaton DM, Berretta RM, Lynch JE, Travers JG, Pfeiffer RD, Hulke ML, Zhao H, Hobby ARH, Schena G, Johnson JP, Wallner M, Lau E, Lam MPY, Woulfe KC, Tucker NR, McKinsey TA, Wolfson MR, Houser SR. Sex-specific responses to slow progressive pressure overload in a large animal model of HFpEF. Am J Physiol Heart Circ Physiol. 2022 10 01; 323(4):H797-H817.
Score: 0.079
-
Wallner M, Eaton DM, Berretta RM, Liesinger L, Schittmayer M, Gindlhuber J, Wu J, Jeong MY, Lin YH, Borghetti G, Baker ST, Zhao H, Pfleger J, Blass S, Rainer PP, von Lewinski D, Bugger H, Mohsin S, Graier WF, Zirlik A, McKinsey TA, Birner-Gruenberger R, Wolfson MR, Houser SR. HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction. Sci Transl Med. 2020 01 08; 12(525).
Score: 0.065
-
Ali HR, Michel CR, Lin YH, McKinsey TA, Jeong MY, Ambardekar AV, Cleveland JC, Reisdorph R, Reisdorph N, Woulfe KC, Fritz KS. Defining decreased protein succinylation of failing human cardiac myofibrils in ischemic cardiomyopathy. J Mol Cell Cardiol. 2020 01; 138:304-317.
Score: 0.065
-
Alexanian M, Padmanabhan A, McKinsey TA, Haldar SM. Epigenetic therapies in heart failure. J Mol Cell Cardiol. 2019 05; 130:197-204.
Score: 0.062
-
Sucharov CC, Nakano SJ, Slavov D, Schwisow JA, Rodriguez E, Nunley K, Medway A, Stafford N, Nelson P, McKinsey TA, Movsesian M, Minobe W, Carroll IA, Taylor MRG, Bristow MR. A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium. J Am Coll Cardiol. 2019 03 19; 73(10):1173-1184.
Score: 0.062
-
Jeong MY, Lin YH, Wennersten SA, Demos-Davies KM, Cavasin MA, Mahaffey JH, Monzani V, Saripalli C, Mascagni P, Reece TB, Ambardekar AV, Granzier HL, Dinarello CA, McKinsey TA. Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. Sci Transl Med. 2018 02 07; 10(427).
Score: 0.057
-
Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, Huang Y, Zhang R, Sahadevan A, Lemieux ME, Brown JD, Srivastava D, Bradner JE, McKinsey TA, Haldar SM. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci Transl Med. 2017 05 17; 9(390).
Score: 0.055
-
Hooker JM, Strebl MG, Schroeder FA, Wey HY, Ambardekar AV, McKinsey TA, Schoenberger M. Imaging cardiac SCN5A using the novel F-18 radiotracer radiocaine. Sci Rep. 2017 02 16; 7:42136.
Score: 0.054
-
McKinsey TA. The biology and therapeutic implications of HDACs in the heart. Handb Exp Pharmacol. 2011; 206:57-78.
Score: 0.035
-
Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp. 2006; 274:3-12; discussion 13-9, 152-5, 272-6.
Score: 0.025
-
McKinsey TA, Olson EN. Cardiac histone acetylation--therapeutic opportunities abound. Trends Genet. 2004 Apr; 20(4):206-13.
Score: 0.022
-
Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 1999 Apr 02; 84(6):735-40.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|